Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Ottmann, Oliver, Saglio, Giuseppe, Apperley, Jane F., Arthur, Christopher, Bullorsky, Eduardo, Charbonnier, Aude, Dipersio, John F., Kantarjian, Hagop, Khoury, Hanna Jean, Kim, Dong-Wook, Healey, Diane, Strauss, Lewis and Cortes, Jorge E. 2018. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer Journal 8 (9) , 88. 10.1038/s41408-018-0122-3

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (414kB) | Preview

Abstract

Treatment with a frontline BCR-ABL1 tyrosine kinase inhibitor (TKI; e.g., imatinib, dasatinib, and nilotinib) allows patients with chronic myeloid leukemia (CML) in chronic phase (CP) to achieve a near normal life expectancy1, whereas treatment for CML in accelerated phase (AP) is more problematic. While reports describe outcomes for patients with CML-AP at initial diagnosis2,3, outcomes have been historically worse once CP disease has progressed to AP. Approximately 50% of patients with CML-AP who receive imatinib as initial treatment develop imatinib resistance4 and experience disease progression5. Second-generation TKIs are indicated for patients with CML-CP or advanced CML resistant to/intolerant of prior therapy (including imatinib)6. After initial approval of dasatinib twice a day (BID) for the treatment of patients with CML resistant to/intolerant of imatinib in all stages, this phase 3 CA180-035 study (NCT00123487) was developed to investigate once (QD) or twice (BID) a day dasatinib treatment in patients with CML-AP, CML in blast phase, or Ph+ acute lymphoblastic leukemia resistant to/intolerant of imatinib.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Additional Information: Open Access This article is licensed under a Creative Commons Attribution 4.0 International License
Publisher: Springer Nature
ISSN: 2044-5385
Date of First Compliant Deposit: 7 January 2019
Date of Acceptance: 8 September 2018
Last Modified: 11 Jul 2019 14:05
URI: http://orca.cf.ac.uk/id/eprint/118157

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics